4 August 2025

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Notice of AGM and EMI Option Plan

CRISM Therapeutics Corporation (AIM:CRTX) confirms that the Annual General Meeting ("AGM") will take place at 11:00am on Tuesday 26 August 2025 at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT.  Further details are set out in the Notice of AGM, which has been posted to shareholders today.

A copy Notice of AGM can be accessed from the Company´s website at:

https://www.crismtherapeutics.com/documents-and-notices

EMI Option Plan

Included within the Notice of AGM is a resolution for a proposed Enterprise Management Incentives Option Plan (the "EMI Option Plan"). The EMI Option Plan is intended to be used to help recruit, retain and incentivise key talent and align employee and shareholder interests by providing eligible employees with the opportunity to acquire ordinary shares in CRISM at a fixed price. There are also schedules to the EMI Option Plan which enable the Company to grant non-tax favoured unapproved options to certain people who are engaged by the Group, including advisors, consultants and non-executive directors, but who would not be eligible to receive tax-favoured EMI options under the EMI Option Plan. 

Options under the EMI Option Plan would vest in three equal portions over a two-year period and be exercisable on the second anniversary of their vesting. The exercise price is expected to be the closing price of the underlying shares on the day prior to the grant, as may be agreed with HMRC from time to time. Options would lapse after 10 years. The total of options granted under the EMI Option Plan will be limited to a maximum of 10% of the Company's issued share capital.

All directors are eligible to receive options in the Company under the EMI Option Plan, which is considered a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. The Company's Nominated Adviser, SP Angel Corporate Finance LLP, considers the terms of the EMI Option Plan and director eligibility to receive options pursuant to the EMI Option Plan to be fair and reasonable insofar as CRISM's shareholders are concerned.

-Ends-

Enquiries:

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.